Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-063970
Filing Date
2025-05-06
Accepted
2025-05-06 07:40:20
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q okur-20250331.htm   iXBRL 10-Q 2498838
2 EX-31.1 okur-ex31_1.htm EX-31.1 17821
3 EX-31.2 okur-ex31_2.htm EX-31.2 17780
4 EX-32.1 okur-ex32_1.htm EX-32.1 15777
  Complete submission text file 0000950170-25-063970.txt   7246042

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT okur-20250331.xsd EX-101.SCH 955971
68 EXTRACTED XBRL INSTANCE DOCUMENT okur-20250331_htm.xml XML 913697
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40315 | Film No.: 25915270
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)